Schering-Plough Corporation (NYSE: SGP) reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson’s disease experiencing motor fluctuations and abnormal involuntary movements (dyskinesias). The trial results were presented at the company’s 2008 R&D Update meeting being hosted for analysts and portfolio managers at company headquarters.

More: continued here

This entry was posted on Tuesday, November 25th, 2008 at 3:11 pm and is filed under Clinical Trials. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.